Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2979-2988

  Yoneda, Toshiyuki ^a   Michigami, Toshimi ^b   Yi, Bing ^a   Williams, Paul J ^a   Niewolna, Maria ^a   Hiraga, Toru ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Breast carcinoma; Osteoclasts; Osteolytic bone metastasis; Osteosclerotic bone metastasis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; TEGAFUR; URACIL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BONE METASTASIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034660140     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2979::aid-cncr13>3.0.co;2-u     Document Type: Conference Paper

References (41)

1. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGFβ signaling blockade inhibits PTH-rP secretion by breast cancer cells and bone metastasis development. J Clin Invest 1999;103:197-206.
2. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclasts formation. Endocrinology 1999;140: 4451-8.
3. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop 1995;312:34-44
4. Mundy GR, Yoneda T. Bisphosphonates as anticancer drug. N Engl J Med 1998;339:357-63.
5. Yoneda T. Mechanisms of preferential metastasis of breast cancer to bone. Int J Oncol 1996;9:103-9.
6. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998;34: 240-5.
7. Fleish H. Bisphosphonates: mechanism of action. Endocrinol Rev 1998;19:80-100.
8. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
9. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
10. Lipton A. Bisphosphonates and breast cancer. Cancer 1997; 80:1668-73.
11. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80:1674-9.
12. Bataille R. Management of myeloma with bisphosphonates. N Engl J Med 1996;334:529-35.
13. Berenson JR, Lichtehstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
14. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998;16:1218-25.
15. Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
16. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleish H, et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998;16:3890-9.
17. Theriault RL, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17:846-54.
18. McCloskey EV, Powles T, Paterson AHG, Ashley S, Kanis JA. Clodronate reduces incidence of skeletal metastases in women with primary breast cancer. Bone 1998;23(Suppl): S189.
19. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI. Bisphosphonate induces apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997;98:665-72.
20. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
21. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-9.
22. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
23. Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smals AGH, Benraad ThJ. Breast cancer study group. Breast Cancer Res Treat 1991;18:27-32.
24. Milch RA, Changus GW. Response of bone to tumor invasion. Cancer 1956;9:340-51.
25. Kamby C, Andersen J, Ejlertsen B, Birkler NE, Rytter L, Zedeler K, et al. Histological grade and steroid receptor content of primary breast cancer - impact on prognosis and possible modes of action. Br J Cancer 1988;58:480-6.
26. Urwin GH, Percival RC, Harris S, Beneton MNC, Williams JL, Kanis SA. Generalized increase inbone resorption in carcinoma of the prostate. Eur J Urol 1985;57:721-3.
27. Clarke NW, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
28. Pecherstorfer M, Ludwig H, Zimmer-Roth H, Schiling T, Woitge HW, Schmidt H et al. The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995;121:542-8.
29. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone disease in breast cancer. Breast Cancer Res Treat 1994;32:73-84.
30. Yoneda T. Arterial microvascularization and breast cancer colonization in bone. Histol Histopathol 1997;12:1145-9.
31. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997;99:2509-17.
32. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-1405.
33. Lelekakis M, Moseley JM, Martin JM, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-70.
34. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-7.
35. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-87.
36. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96:133-8.
37. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-transitional prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-9.
38. Kostenuik PJ, Orr FW, Suyama K, Singh G. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonates-treated rats. Cancer Res 1993;53:5452-7.
39. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116-31.
40. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 1998;16:2877-85.
41. Tashiro H, Nomura Y, Ohsaki A. A double blind comparative study of tegafur (FT) and UFT (a comibantion of tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol 1994;24: 212-7.